Detection efficacy of [89Zr]Zr-PSMA-617 PET/CT in [68Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer

[1]  H. Buchholz,et al.  Detection Efficacy of 68Ga-PSMA-11 PET/CT in Biochemical Recurrence of Prostate Cancer with Very Low PSA Levels: A 7-Year, Two-Center “Real-World” Experience , 2023, Cancers.

[2]  H. Jadvar,et al.  Oligometastatic Prostate Cancer: Current Status and Future Challenges , 2022, The Journal of Nuclear Medicine.

[3]  P. Karakiewicz,et al.  The current role of precision surgery in oligometastatic prostate cancer , 2022, ESMO open.

[4]  A. Schaefer-Schuler,et al.  [89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  P. Seifert,et al.  Differences in Distribution and Detection Rate of the [68Ga]Ga-PSMA Ligands PSMA-617, -I&T and -11—Inter-Individual Comparison in Patients with Biochemical Relapse of Prostate Cancer , 2021, Pharmaceuticals.

[6]  Steffie M. B. Peters,et al.  89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  C. Vanhove,et al.  Recent advancements in 18F-labeled PSMA targeting PET radiopharmaceuticals. , 2021, Nuclear medicine and biology.

[8]  A. Drzezga,et al.  Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer , 2021, Molecular Imaging and Biology.

[9]  A. Drzezga,et al.  An 89Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients , 2021, The Journal of Nuclear Medicine.

[10]  T. Holland-Letz,et al.  Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Joon-Kee Yoon,et al.  Current Perspectives on 89Zr-PET Imaging , 2020, International journal of molecular sciences.

[12]  N. Lawrentschuk,et al.  Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. , 2020, European urology.

[13]  M. Schwaiger,et al.  Radiohybrid Ligands: A Novel Tracer Concept Exemplified by 18F- or 68Ga-Labeled rhPSMA Inhibitors , 2019, The Journal of Nuclear Medicine.

[14]  Michael Gordon,et al.  First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting , 2019, The Journal of Nuclear Medicine.

[15]  K. Haustermans,et al.  Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer. , 2019, European urology oncology.

[16]  D. Elashoff,et al.  Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT] , 2019, BMC Cancer.

[17]  Frankis Almaguel,et al.  89Zr-Chloride Can Be Used for Immuno-PET Radiochemistry Without Loss of Antigen Reactivity In Vivo , 2018, The Journal of Nuclear Medicine.

[18]  P. Choyke,et al.  Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy , 2018, The Journal of Nuclear Medicine.

[19]  T. Holland-Letz,et al.  The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[20]  Bernd J. Krause,et al.  68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  B. Hadaschik,et al.  F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  Serge K. Lyashchenko,et al.  89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  D. Bostwick,et al.  Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. , 1998, Urology.

[24]  P. Schellhammer,et al.  Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. , 1995, Urologic oncology.